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Abstract:  Affordability through reduced pricing is only one part of enhancing access to treatment in Public Health 
emergencies: Supply Security and the guarantee of supply consistency is the other. 
To the extent that Patent Pooling is able to create Regional African Manufacturing capability, Africans will support the 
concept. However, to the extent that if further decentralises manufacture away from the continent and increases Africa’s 
dependence on imports, Patent Pooling can potentially weaken supply security and will continue to relegate Africa a 
Continent of dependency, rather than one that invests in its own capability. 
Patent Pooling, should be viewed guardedly on the African Continent and will only be embraced, provided it is consistent 
with the AU Heads of State call for an African Manufacturing Plan and Africa’s aspiration to more from “converting 
charity dollars into sustainable, long term investment dollars”. 
AFRICA SHOULD MANUFACTURE ITS OWN DRUGS 
  Tremendous progress has been made in recent times in 
enhancing and accelerating access to treatment with first line 
ARVs to patients in Sub – Saharan Africa [1, 2]. This has 
largely occurred, as a consequence of the introduction of 
generic products, bought about by the collaboration between 
the R&D based industry and generic producers and the 
ability to drive down raw material prices [3, 4]. 
  To this end, it should be noted that affordability through 
reduced pricing is one aspect of enhancing access to 
treatment, however it is not the only one. 
  A very important aspect to the access of treatment 
debate, is that of supply security. The reduction of price, as 
welcome as it might be, becomes largely meaningless, unless 
supply security and the guarantee in consistency of supply is 
ensured. It is for this reason and others, that the African 
Union heads of state summit in Abudja in 2004 called for an 
African Pharmaceutical manufacturing plan, where the 
establishment of regional pharmaceutical manufacturing 
capability became an alternative to the dependency created 
by Pharmaceutical imports. It seemed that Africa, a 
significant net importer of Pharmaceutical products, 
particularly in those high volume therapeutic areas that are 
endemic to the Sub Saharan region was missing a significant 
opportunity in developing its own Pharmaceutical capacity 
and capability and hence lessening its dependence on 
imports. 
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ENTWINING IMPORTS WITH LOCALLY PRODUCED 
DRUGS 
  The Current trend of importing even the most basic and 
high volume pharmaceuticals continues to exacerbate the old 
adage that Africa is incapable of manufacturing and or 
developing high tech products. This mind set lends itself to 
the continued outflow of skills, technology, capital and 
economic value from the continent to foreign destinations. It 
also places supply security at risk and denies the continent 
developmental opportunities. A model which provides the 
appropriate mix between locally produced products and 
imports is a far more viable and sustainable option in the 
long term. 
  Consequently, whilst patent pools can offer much in 
terms of accelerating access to treatment, particularly in 
those epidemiologies that remain pervasive in Africa, due 
recognition and cognizance of local manufacturing and its 
benefits to both the people and Economies of the Sub 
Saharan region cannot be understated [5]. It stands to reason, 
that Africa needs to develop and entrench its own 
capabilities in those areas that are socio economically critical 
to the continent. Infectious diseases that are endemic on the 
continent, most certainly fall in the category of some of the 
keenest and most important socio economic challenges that 
confront the continent. Africa cannot continue to stand by 
and watch the hitherto culture of developmental dependency, 
as not only does it place its future in the hands of others, but 
this perpetuates the culture of expecting indefinite hand outs 
from Donor funders, rather than taking its future and destiny 
into its own hands. 
THE APPROPRIATE BALANCE 
  The frequently mentioned dictum “Teach a man to fish, 
rather than donating a daily fish and keeping the man   
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without a fishing rod” needs to begin to be applied in the  
context of Pharmaceutical interventions in African Public 
Health emergencies. Voluntary pooling of patents provides 
an ideal opportunity for this to begin occurring and for 
serious attempts at the development of regional 
manufacturing capability to be taken to heart. To the extent 
that patent pooling can contribute to this and the prospects of 
confronting Africa’s socio economic challenges through the 
creation of economic value added beneficiation to the benefit 
of Africa and its people, we need to support it. 
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